Review decision – December 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA369; Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears.

No new evidence has been identified that is likely to change the recommendations in TA369.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, TA369 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: 31 December 2018